- Conditions
- Small Cell Lung Cancer (SCLC), Neuroendocrine (NE) Tumors, Large Cell Neuroendocrine (NE) Tumors
- Interventions
- Rhenium Re 188-P2045
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Healthy Participants
- Interventions
- Admilparant
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Lenexa, Kansas • Salt Lake City, Utah
- Conditions
- Hematologic Neoplasms
- Interventions
- JNJ-95804306, AML SoC, CLL/SLL SoC
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 6
- States / cities
- Indianapolis, Indiana • Grand Rapids, Michigan • Piscataway, New Jersey + 3 more
- Conditions
- Lymphoma
- Interventions
- There is no intervention
- Other
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Advanced Solid Tumors
- Interventions
- BG-C477, Tislelizumab, Chemotherapy
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 10
- States / cities
- Goodyear, Arizona • Duarte, California • Aurora, Colorado + 7 more
- Conditions
- Classical Hodgkin Lymphoma
- Interventions
- Dacarbazine, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pembrolizumab, Vinblastine
- Drug · Other · Biological
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
- Interventions
- ARV-393, Glofitamab
- Drug
- Lead sponsor
- Arvinas Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 329 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 10
- States / cities
- New Haven, Connecticut • Miami, Florida • Detroit, Michigan + 6 more
- Conditions
- Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
- Interventions
- Administration of ceralasertib, Administration of ceralasertib in combination with olaparib, Administation of ceralasertib in combination with durvalumab, Administration of ceralasertib monotherapy, Administration of ceralasertib and olaparib, Administration of ceralasertib and durvalumab, Administration of ceralasertib in combination with AZD5305, Administration of ceralasertib in combination with carboplatin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 8
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 4 more
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Refractory Solid Tumor, Cancer, Lung Cancer, Triple Negative Breast Cancer, Breast Neoplasms, Neuroendocrine Tumors, Neuroendocrine Carcinoma, RB1 Gene Mutation
- Interventions
- CID-078 Monotherapy
- Drug
- Lead sponsor
- Circle Pharma
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 10
- States / cities
- Sarasota, Florida • Boston, Massachusetts • Grand Rapids, Michigan + 7 more
- Conditions
- Adenoid Cystic Carcinoma, Colorectal Cancer
- Interventions
- RGT-61159, lenvatinib
- Drug
- Lead sponsor
- Rgenta Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 7
- States / cities
- Boston, Massachusetts • Ann Arbor, Michigan • New York, New York + 3 more
- Conditions
- Neoplasms
- Interventions
- MK-0482, pembrolizumab, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin, Pemetrexed
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 3
- States / cities
- Detroit, Michigan • Hackensack, New Jersey • San Antonio, Texas
- Conditions
- Head and Neck Cancer
- Interventions
- Neurocognitive Tests, Questionnaires
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Renal Replacement Therapy, Pharmacokinetics
- Interventions
- Cefazolin
- Drug
- Lead sponsor
- Drexel University
- Other
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- T-cell Lymphoma
- Interventions
- Enasidenib, Rituximab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
- Conditions
- Solid Tumors
- Interventions
- AUBE00, Cetuximab
- Drug
- Lead sponsor
- Chugai Pharmaceutical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- Grand Rapids, Michigan • Houston, Texas • Fairfax, Virginia
- Conditions
- Solid Tumor
- Interventions
- Debio 1143, Nivolumab
- Drug
- Lead sponsor
- Debiopharm International SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 11
- States / cities
- Gainesville, Florida • Tampa, Florida • Chicago, Illinois + 7 more
- Conditions
- Functional Constipation
- Interventions
- Linaclotide, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 6 Months to 23 Months
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Hot Springs, Arkansas • Anaheim, California + 14 more
- Conditions
- Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Pleiotropic Pathway Modifier, Glioblastoma, Lymphoma, Primary Central Nervous System Lymphoma
- Interventions
- CC-122
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2023
- U.S. locations
- 17
- States / cities
- Duarte, California • Los Angeles, California • San Francisco, California + 13 more
- Conditions
- Sarcoma, Melanoma, Non-small Cell Lung Cancer, Ovarian Cancer
- Interventions
- CMB305, G100, Metronomic CPA
- Biological · Drug
- Lead sponsor
- Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 8
- States / cities
- Santa Monica, California • New Haven, Connecticut • Tampa, Florida + 5 more
- Conditions
- Macular Degeneration
- Interventions
- RO6867461
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 5
- States / cities
- Colorado Springs, Colorado • Baltimore, Maryland • Dallas, Texas + 2 more
- Conditions
- Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Renal Cell Carcinoma
- Interventions
- FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 6
- States / cities
- Palo Alto, California • Chicago, Illinois • Omaha, Nebraska + 3 more
- Conditions
- Colorectal Cancer (Locally Advanced or Metastatic)
- Interventions
- SOT109
- Biological
- Lead sponsor
- SOTIO Biotech a.s.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Houston, Texas • Faifax, Virginia
- Conditions
- Renal Cell Cancer, Melanoma, Non-Small-Cell Lung Cancer, Hepatocellular Cancer, Bladder Cancer, Sarcoma, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer, Squamous Cell Carcinoma
- Interventions
- PF-07263689, Sasanlimab
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 3
- States / cities
- Duarte, California • New York, New York
- Conditions
- Lymphoma
- Interventions
- Extracorporeal Photopheresis, Pentostatin, Total body irradiation (TBI), Allogeneic bone marrow transplantation, Cyclosporin (CSA), Mycophenolate mofetil (MMF), Methotrexate (MTX)
- Procedure · Drug · Radiation
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 19
- States / cities
- Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 12 more